Drugs.com - Clinical Trials

Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States

NEW YORK, N.Y. (April 15, 2025) – Click Therapeutics, Inc., (“Click”) a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug™ therapies, has obtained FDA marketing...

Apr 22, 2025 - 02:22
 0
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
NEW YORK, N.Y. (April 15, 2025) – Click Therapeutics, Inc., (“Click”) a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug™ therapies, has obtained FDA marketing...
Read More

Tags:

Previous Article

Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in O...

Next Article

Yanran Chen’s Art Goes Beyond Cyborgs and Cyberpunk Collectables

Related Posts

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

Vivani Medical Achieves First Implant and Full Enrollme...

Mar 18, 2025  0

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Salarius Pharmaceuticals Announces Patient Enrollment t...

Feb 9, 2025  0

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology

Findings From Pivotal Nipocalimab Phase 3 Study in a Br...

Feb 9, 2025  0